GamEvac-Combi

GamEvac-Combi (Russian: ГамЭвак-Комби) is a heterologous VSV- and Ad5-vectored Ebola vaccine. There is also a version called GamEvac which is a homologous Ad5-vectored vaccine.[1] GamEvac-Combi was developed by Gamaleya Research Institute of Epidemiology and Microbiology. As of 2015 the vaccine has been licensed in Russia for emergency use, on the basis of Phase 1 and Phase 2 clinical trials.[2]

GamEvac-Combi
Vaccine description
Target diseaseEbola
TypeHeterologous VSV- and Ad5-vectored
Legal status
Legal status
  • registered (Russia)

Description

The vaccine consists of live-attenuated recombinant vesicular stomatitis virus (VSV) and adenovirus serotype-5 (Ad5) expressing Ebola envelope glycoprotein.[3] The vaccine is targeted against the Makona variant of Ebola that was circulating in West Africa during the 2013-2016 outbreak.[4]

History

GamEvac-Combi was licensed by the Ministry of Health of the Russian Federation for emergency use in the territory of the Russian Federation in December 2015. The emergency license was based on Phase I and II clinical data of safety and immunogenicity.[2]

See also

References
  1. Dolzhikova, I. V.; Tokarskaya, E. A.; Dzharullaeva, A. S.; Tukhvatulin, A. I.; Shcheblyakov, D. V.; Voronina, O. L.; Syromyatnikova, S. I.; Borisevich, S. V.; Pantyukhov, V. B.; Babira, V. F.; Kolobukhina, L. V.; Naroditsky, B. S.; Logunov, D. Y.; Gintsburg, A. L. (2017). "Virus-Vectored Ebola Vaccines". Acta Naturae. 9 (3): 4–11. doi:10.32607/20758251-2017-9-3-4-11. PMC 5662269. PMID 29104771.
  2. "Update with the development of Ebola vaccines and implications of emerging evidence to inform future policy recommendations" (PDF). World Health Organization. Retrieved 14 August 2020.
  3. Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, Shmarov MM, Tokarskaya EA, Simakova YV, Egorova DA, Scherbinin DN, Tutykhina IL, Lysenko AA, Kostarnoy AV, Gancheva PG, Ozharovskaya TA, Belugin BV, Kolobukhina LV, Pantyukhov VB, Syromyatnikova SI, Shatokhina IV, Sizikova TV, Rumyantseva IG, Andrus AF, Boyarskaya NV, Voytyuk AN, Babira VF, Volchikhina SV, Kutaev DA, Bel'skih AN, Zhdanov KV, Zakharenko SM, Borisevich SV, Logunov DY, Naroditsky BS, Gintsburg AL (March 2017). "Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia". Hum Vaccin Immunother. 13 (3): 613–620. doi:10.1080/21645515.2016.1238535. PMC 5360131. PMID 28152326.
  4. Malvy, Denis; McElroy, Anita K; de Clerck, Hilde; Günther, Stephan; van Griensven, Johan (March 2019). "Ebola virus disease". The Lancet. 393 (10174): 936–948. doi:10.1016/s0140-6736(18)33132-5. ISSN 0140-6736. PMID 30777297.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.